Blue Owl Capital Holdings LLC – Trademark Portfolio
Entity Type: 16
Blue Owl Capital Holdings LLC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 7 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include BLUE OWL, BLUE OWL CAPITAL, and REDEFINING ALTERNATIVES. The owner is based in New York, NY.
38th Floor
399 PARK AVENUE
New York, NY 10022
Showing of trademarks Trademarks
Trademark Classifications
Blue Owl Capital Holdings LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Blue Owl Capital Holdings LLC have?
Blue Owl Capital Holdings LLC has 7 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned.
What trademark classes does Blue Owl Capital Holdings LLC file in?
Blue Owl Capital Holdings LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 35 (Advertising & Business). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are Blue Owl Capital Holdings LLC's most well-known trademarks?
Blue Owl Capital Holdings LLC's registered trademark portfolio includes well-known marks such as BLUE OWL, BLUE OWL CAPITAL, and REDEFINING ALTERNATIVES. These are among 6 currently registered trademarks in the portfolio.
What is Blue Owl Capital Holdings LLC's trademark registration success rate?
Blue Owl Capital Holdings LLC has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.